Remove 2016 Remove Negotiation Remove Public Trading
article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company. In response to calls from the White House, the FTC also is going beyond traditional enforcement and exploring entirely new approaches to enforcement in the life sciences industry.

M&A 40
article thumbnail

Transfer Traps: Considerations for Dual-Class Companies Contemplating M&A Transactions

Cooley M&A

4] However, such exceptions were not universal and, as will be discussed below, the vast majority of dual-class charters adopted before 2016 that contained transfer restrictions did not include M&A voting agreement carve outs. Voting agreements in public M&A transactions. Vote-down termination fee (i.e., a ’naked no-vote fee’).

M&A 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Keeping Up with Delaware Appraisal Jurisprudence Since Aruba: Deal Price Reigns Supreme, But Will Recent Decision Lead to More Arbitrage?

Cooley M&A

In an effort to reduce appraisal arbitrage, Delaware amended the appraisal statute in 2016 to permit companies to prepay the deal price, stopping the clock on the statutory interest accrual. Panera Bread was a publicly traded company that JAB Holdings B.V. took private in 2017 for $315/share.

article thumbnail

Cooley’s 2021 Life Sciences M&A Year in Review

Cooley M&A

A healthy 90 biopharma M&A transactions were announced in 2021 (compared to 69 in 2020 and 70 in 2019, the most transactions since 2016). on transactions over 2019’s mega?mergers. But deal value – which totaled $108 billion as of December 15, 2021 – was slightly down from 2020 and significantly down from 2019.

M&A 40